Ritanserin in the treatment of alcohol dependence – a multi-center clinical trial

Four hundred and twenty-three alcohol dependent subjects were enrolled into a 12-week randomized, double-blind, placebo-controlled study to determine the safety and efficacy of the 5-HT₂ receptor antagonist, ritanserin (2.5 mg/day or 5 mg/day), in reducing alcohol intake and craving. All subjects received 1 week of single-blind placebo prior to randomization into the 11-week double-blind phase. Additionally, all subjects received weekly individual sessions of manual-guided cognitive-behavioral therapy. Comparing the single-blind period with endpoint, there was approximately a 23% reduction in drinks/day; 34% fall in the total number of drinking days/week; 22% decrease in drinks/drinking day; and a 37% diminution in alcohol craving for all treatment groups. All treatment groups experienced a beneficial clinical outcome as assessed by the Clinical Global Impression Scale. There was, however, no significant difference between treatment groups on any of these measures of alcohol drinking, craving, or clinical outcome. Subjects were of relatively high social functioning at baseline, and this did not change significantly during treatment. Treatment groups did not differ significantly on either medication compliance or reported adverse events. Ritanserin treatment was associated with a dose-related prolongation of subjects’ QTc interval recording on the electrocardiogram. These results suggest that alcohol dependent subjects can show marked clinical improvement within a structured alcohol treatment program. These findings do not support an important role for ritanserin in the treatment of alcohol dependence. Received: 30 April 1996/Final version: 3 July 1996     

良性小脑出血13例分析

笔者对13例良性小脑出血的患者,从起病、临床表现进行了具体分析.总结出中老年良性小脑出血的6个特点,供临床工作者参考.     

Comparison of gas-liquid chromatography and EMIT assay for serum valproic acid

We describe a simple direct extraction method for the gas-liquid chromatography determination of serum valproic acid. The working range for the assay is 2-180 mg/L and our within-run precision was 5.8 and 4.3% at the 40 and 90 mg/L concentrations respectively. Hemolyzed and lipemic sera as well as samples from patients with hyperbilirubinemia and from patients with decreased renal function were put through the assay and no interfering peaks were noted. Interference occurred when teflon-lined screw caps were used during the extraction step. The method was proven to be accurate by linear regression analysis of samples containing weighed-in amounts of valproic acid. The above assay was compared to an enzyme immunoassay technique (EMIT). The working range for the latter is 10-150 mg/L and the with-run precision was 10.8 and 5.9% and 90 mg/L concentration respectively. Samples were run by both the gas-liquid chromatograph and enzyme immunoassay methods and gave very similar results over the range 16-139 mg/L.     

中西医结合治疗难治性原发性肾病综合征20例

目的 :探讨难治性原发性肾病综合征 ( PNS)的中西医结合治疗途径。方法 :选择 PNS患者2 0例 ,逐步撤减激素至停用 ,停免疫抑制剂 ,酌情给予降压、利尿、降脂、提高血浆胶体渗透压 ,自拟“健肾汤”、辨证辨病加减 ,治疗前后分别测定 2 4 h尿蛋白定量、血浆白蛋白、胆固醇、Scr(血肌酐 )、Ccr(肌酐清除率 )。结果 :治疗 8周后 2 4 h尿蛋白、血浆胆固醇显著下降 ,血浆白蛋白显著上升 ,肾功能明显改善 ( P<0 .0 1 )。病情完全缓解 40 % ,部分缓解 45 % ,无效 1 5 % ,总有效率 85 %。结论 :中西医结合治疗 PNS取得一定疗效 ,值得临床和实验进一步研究。     

绝经前后T1期乳腺癌患者临床特征的分析

目的:分析T1期(肿瘤直径<2cm)原发性乳腺癌女性患者绝经前后在肿瘤大小、病理分类、淋巴结转移率和数目。方法:常规病理检验以及应用免疫组化、HE法分别测定绝经前乳腺癌患者和绝经后乳腺癌患者者的ER、PR。结果:两组患者在肿瘤大小上无明显差异,但绝经前乳腺癌患者浸润导管癌的百分比为 84. 7%,绝经后乳腺癌患者的浸润导管癌百分比为 62. 2%,经χ2 检验,P<0. 01。两组淋巴结转移率分别为 39. 3%和 25. 5%,经χ2 检验,P<0. 01。两组ER和PR阳性伴淋巴结转移的比例经χ2 检验,P<0. 05。结论:绝经前乳腺癌患者和绝经后乳腺癌患者在病理分类、淋巴结转移率及数目、ER、PR阳性伴淋巴结转移上有显著性差异。对于T1原发性乳腺癌患者不论有无淋巴结转移,均应行癌肿切除伴Ⅰ、Ⅱ级淋巴结清扫。     

从事全胃肠外营养工作的心得

目的:交流从事全胃肠外营养(TPN)工作的心得。方法:查阅近年来相关国内外文献,结合自己的工作实践进行回顾、总结和分析。结果与结论:从事TPN工作的临床药师应不断接受业务教育,凭借专业优势与临床加强联系,善于分析、总结临床信息,推动临床药学发展。     

深圳市南山区医疗机构消毒效果分析

目的:了解南山区各医院及个体诊所卫生消毒状况。方法:对2002~2003年间区属各医院及个体诊所消毒效果的监测结果进行统计分析。结果:2002年与2003年区镇医院消毒效果平均合格率分别为94.4%和97.1%,个体诊所平均合格率分别为87.6%和89.8%。结论:区(镇)医院消毒效果优于个体诊所,空气合格率普遍较低,卫生防疫机构要加大力度进行监督检测,同时加强对医务人员进行消毒知识培训。     

冬凌草单药及与化疗合用治疗食管癌205例

目的:观察冬凌草单药及与化疗合用治疗食管癌的临床疗效.方法:448例患者,均经病理细胞学和X线检查确诊为食管癌.其中早期癌76例,均采用冬凌草单药治疗.晚期癌372例,167例采用冬凌草单药治疗,205例采用冬凌草与化疗合用.结果:用冬凌草单药治疗早期食管癌患者3,5,10,13 a的生存率明显高于未治疗组(98.68% vs 51.52%,84.02% vs 28.62%,63.49% vs 11.45%,50.13% vs 8.59%;P<0.001).对于晚期食管癌,冬凌草联合化疗应用,其总有效率明显高于以PYM(BLM)为基础的单一化疗(66.82% vs 42.85%,P<0.01).冬凌草与化疗合用组与单一化疗对照组相比副作用基本相同,无明显差异(P>0.05).结论:对于早期食管癌患者,冬凌草能控制疾病发展延长生存时间;对于晚期食管癌患者,冬凌草能增强化疗的作用.